Obi Pharma, Inc. · TPEX:4174
Obi Pharma — Investment Summit of BIO Asia-Taiwan 2025
12 slides from Obi Pharma's conference presentation, Jul 1, 2025
Slide 1: OBI Pharma: Innovation in Action
OBI Pharma Innovation in Action Investment Summit of BIO Asia-Taiwan 2025 Chief Executive Officer Heidi Wang, Ph.D. 1 July 2025 © 2025 OBI Pharma Inc. All Rights Reserved.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as “believes,” “expects,” “anticipates, ” “ projects,” “ intends,” “should,” “seeks,” “estimates,” “ future ,” “or similar expressions or by discussio
Slide 3: Company Overview
Taipei Company Overview TAIWAN • Established in 2002 • Listed in 2013 (4174.TWO) • Headquartered in Taipei, Taiwan Melbourne San Diego AUSTRALIA USA • Focus on “first-in-class” and “best-in-class” ADCs • Talents in Asia and the U.S. • >80% with advanced degrees* www.obipharma.com 3 July 2025 *Master
Slide 4: Experienced Leaders in Drug Development
Experienced Leaders in Drug Development Executive Team Heidi Wang, PhD Ya-Chi Chen, PharmD Kevin Poulos Chief Executive Officer Chief Scientific Officer Chief Business Officer Dong Xu, PhD Colin Kao, CPA Chief Medical Officer Chief Operating Officer 4 July 2025
Slide 5: Precision Medicine: ADCs Deliver Drugs Selectively to Cancer Cells
Precision Medicine: ADCs Deliver Drugs Selectively to Cancer Cells Obrion Engine Antibody 7+ Years of ADC Experience Selectively binds to target on cancer cells Payload C Drug that kills cancer cells C Masking effect VISION N Right Patient Linker Right Drug Connects antibody to payload Right Time 5
Slide 6: July 2025
ADC recognizes \_ Ne ~ Payload i is rele and the target and \ ~ cancer cell is killed enters the cell ?
Slide 7: Broad Oncology Pipeline with a Focus on ADC
Broad Oncology Pipeline with a Focus on ADC Modality Program Indication Preclinical Ph 1 Ph 2 Ph 3 Next Dev. Milestone OBI-992 Ph1 Readout (TROP2 ADC via Cys conjugation) Mono 2025 US FDA IND OBI-902 Advanced TFDA IND Approved Ph 1 First Patient In (TROP2 ADC via ) Solid Tumors ADC OBI-904 IND (Nect
Slide 8: Exhibits Promising Antitumor Activities
Exhibits Promising Antitumor Activities Innovation Leads to a New Era of Precision Therapies Colorectal Cancer CDX 1750 1500 T u m o r v o lu m e ( m m ) 3 HER3-DXd1 2 5 0 EmrelisTM 1000 EmrelisTM + HER3-DXd 750 500 250 cMET 0 x HER3 cMET HER3 1 4 8 11 15 18 21 24 D a y s a fte r tre a tm e n t V e
Slide 9: Multi-platform Next-generation ADC Technologies
Multi-platform Next-generation ADC Technologies ADCs: the ultimate designer drugs to bring precision medicine to patients Dual function enzyme with One-Pot engineering Glycan site-specific platform Next generation Cysteine-based Obrion platform Engine ▪ MsADC & BsADC ▪ Dual-payload ADC ▪ DAC ▪ AOC G
Slide 10: ASK: Investment Welcome!
ASK: Investment Welcome! Innovative Products and Enabling Technologies OBI Pipeline Assets Out-License OBI-992, OBI 902 – Novel TROP2 ADCs License OBI-904 – Novel Nectin-4 ADCs Agreement Bispecific, Single/ Dual-Payload ADCs – TROP2 x HER2, c-MET x HER3 Enabling Technologies Out-License (product can
Slide 11: Investment Welcome! Innovation in Action
Investment Welcome! Innovation in Action www.obipharma.com InvestorRelations@obipharma.com 11 July 2025
Slide 12: Our Global Partners
Our Global Partners Other Potential Collaborations 12 July 2025 Image generated by Microsoft Copilot
OBI Pharma — Investment Summit of BIO Asia-Taiwan 2025 on 6ix